Desarrollo de inmunidad humoral en personas infectadas por SARS-COV-2
DOI:
https://doi.org/10.35381/s.v.v6i1.1727Palabras clave:
Inmunidad humoral, inmunología, anticuerpos. (Fuente, DeCS).Resumen
Objetivo: Analizar el desarrollo de inmunidad humoral en personas infectadas por SARS-COV-2 de las ciudades Quito y Ambato del Ecuador. Método: Estudio observacional de pacientes reales diagnosticados con Covid-19, se tabularon un total de 31 pacientes sometidos a pruebas nasofaríngeas. Resultados: El hallazgo de que una prueba de anticuerpos que da positivo sugiere que el riesgo de reinfección sea subjetivamente bajo; no obstante, los individuos que se recuperan de una infección por el SARS-CoV-2 todavía poseen restos de material del virus es decir ácido ribonucleico o ARN en el cuerpo humano por lo menos 3 meses. Conclusión: Las personas estudiadas generan cierta inmunidad humoral; las primeras respuestas humorales específicas del SARS-CoV-2 estuvieron dominadas por anticuerpos IgM, a medida que la infección progresa hasta el término de los síntomas; sin embargo; se necesitan de varios estudios para demostrar que las personas infectadas por el coronavirus Covid-19, tengan anticuerpos neutralizantes Anti-Spike.
Descargas
Citas
Singh R, Kang A, Luo X, et al. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 2021;35(3):e21409. doi:10.1096/fj.202002662R
Lee E, Oh JE. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. Mol Cells. 2021;44(6):392-400. doi:10.14348/molcells.2021.0075
Lucas C, Klein J, Sundaram M, et al. Kinetics of antibody responses dictate COVID-19 outcome. Preprint. medRxiv. 2020;2020.12.18.20248331. Published 2020 Dec 22. doi:10.1101/2020.12.18.20248331
Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Preprint. medRxiv. 2020;2020.03.17.20037713. Published 2020 Apr 16. doi:10.1101/2020.03.17.20037713
Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437-442. doi:10.1038/s41586-020-2456-9
Lucas C, Klein J, Sundaram M, et al. Kinetics of antibody responses dictate COVID-19 outcome. Preprint. medRxiv. 2020;2020.12.18.20248331. Published 2020 Dec 22. doi:10.1101/2020.12.18.20248331
Pathak E. Convalescent plasma is ineffective for covid-19 Lessons. BMJ 2020;371:m4072 Available from: https://www.bmj.com/content/371/bmj.m4072.long
Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [published correction appears in BMJ. 2020 Nov 3;371:m4232]. BMJ. 2020;371:m3939. Published 2020 Oct 22. doi:10.1136/bmj.m3939
CDC. Interim Guidelines for COVID-19 Antibody Testing. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings. [Internet]. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020;57(1):e100. doi:10.1002/cpmc.100
Peterhoff D, Glück V, Vogel M, et al. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection. 2021;49(1):75-82. doi:10.1007/s15010-020-01503-7
Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027-2034. doi:10.1093/cid/ciaa344
Taefehshokr N, Taefehshokr S, Heit B. Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. Pathogens. 2020;9(12):1027. Published 2020 Dec 8. doi:10.3390/pathogens9121027
Wei J, Zhao J, Han M, Meng F, Zhou J. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. J Immunother Cancer. 2020;8(2):e000862. doi:10.1136/jitc-2020-000862
Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-1036. doi:10.1038/s41591-020-0913-5
Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791-797. doi:10.1099/jgv.0.001439
Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020;53(2):248-263. doi:10.1016/j.immuni.2020.07.005
İnandıklıoğlu N, Akkoc T. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2. Adv Exp Med Biol. 2020;1288:5-12. doi:10.1007/5584_2020_549
De León-Rodríguez SG, Hernández-Rico B, Olmo-Vázquez GD, Cruz-Dávalos I, Bonifaz LC. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines. SARS-CoV-2: coronavirus previos, respuesta inmune y desarrollo de vacunas. Bol Med Hosp Infant Mex. 2020;77(5):252-261. doi:10.24875/BMHIM.20000191
Al-Kassmy J, Pedersen J, Kobinger G. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?. Viruses. 2020;12(8):861. Published 2020 Aug 7. doi:10.3390/v12080861
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. Published 2021 May 13. doi:10.1136/bmj.n1088
Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021;21(11):1529-1538. doi:10.1016/S1473-3099(21)00289-9
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10226):809-815. doi:10.1016/S0140-6736(20)30360-3
Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med. 2012;2(3):a007724. doi:10.1101/cshperspect.a007724
Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-455. doi:10.1111/all.14657
Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-1839. doi:10.1016/j.jiph.2020.07.014
Triggle CR, Bansal D, Ding H, et al. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021;12:631139. Published 2021 Feb 26. doi:10.3389/fimmu.2021.63113
Hirotsu Y, Maejima M, Shibusawa M, et al. Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. Int J Infect Dis. 2020;99:397-402. doi:10.1016/j.ijid.2020.08.029
Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now?. Acta Trop. 2021;214:105778. doi:10.1016/j.actatropica.2020.105778
Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-2332. doi:10.1056/NEJMoa2026920
Publicado
Cómo citar
Número
Sección
Licencia
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
